In spite of a large number of transforming growth factor b1 (TGF-b1)-regulated genes, the nature of its targets with roles in transformation continues to be poorly understood. Here, we discovered that TGF-b1 stimulates transcription of metastasis-associated protein 1 (MTA1), a dual master coregulator, in epithelial cells, and that MTA1 status is a determinant of TGF-b1-induced epithelial-to-mesenchymal transition (EMT) phenotypes. In addition, we found that MTA1/polymerase II/activator protein-1 (AP-1) co-activator complex interacts with the FosB-gene chromatin and stimulates its transcription, and FosB in turn, utilizes FosB/histone deacetylase 2 complex to repress E-cadherin expression in TGF-b1-stimulated mammary epithelial cells. These findings suggest that TGF-b1 regulates the components of EMT via stimulating the expression of MTA1, which in turn, induces FosB to repress E-cadherin expression and thus, revealed an inherent function of MTA1 as a target and effector of TGF-b1 signaling in epithelial cells.
Introduction
Inappropriate transforming growth factor b1 (TGF-b1)-signaling has been linked with dedifferentiation, epithelial-mesenchymal transition (EMT) and tumor progression (Condeelis and Segall, 2003; Peinado et al., 2003) . During EMT, epithelial cells lose their polarity and repress E-cadherin but express mesenchymal markers such as vimentin and a-smooth muscle actin (a-SMA) (Thiery, 2002; Radisky, 2005; Zavadil and Bottinger, 2005; Hugo et al., 2007) . The process of cancer progression involves a rapid modulation of TGF-b1-responsive genes with roles in EMT and metastasis via remodeling of target gene chromatin in response to upstream signals. The TGF-b1-signaling is largely mediated by Smad proteins (Massague et al., 2005) where Smad2 and Smad3 are phosphorylated by TGF-b1-receptors and associate with the common mediator Smad4, which translocates to the nucleus to participate in the expression of TGF-b1-target genes (Deckers et al., 2006) . Previous studies have shown that CUTL1, also known as CDP (CCAAT displacement protein), a target of TGF-b1, is needed for its short-term effects of TGF-b1 on cell motility involving Smad4-dependent pathway (Michl et al., 2005) .
In addition to TGF-b1-signaling, the process of breast cancer progression is profoundly influenced by the levels of metastasis-associated protein 1 (MTA1), an integral role in nucleosome remodeling and histone deacetylation complex (Manavathi and Kumar, 2007) . The MTA1 regulates the transcriptional outcome of its targets because of its ability to modify the acetylation status on the target gene chromatin and thus, controlling accessibility of various coregulators to DNA (Gururaj et al., 2006) . In addition of its interaction with histone deacetylases (HDACs) and nucleosome remodeling and histone deacetylation complex, it functions as a corepressor on its targets (Mazumdar et al., 2001; Molli et al., 2008) , where as MTA1 also interacts with RNA polymerase II (Pol II) and acts as a co-activator on some targets (Gururaj et al., 2006; Balasenthil et al., 2007) . Earlier studies from this and other laboratories have shown that increased MTA1 expression in murine mammary epithelial or tumor cells is associated with not only increased invasiveness but also a reduced expression of E-cadherin, a hallmark of EMT Tong et al., 2007; Dannenmann et al., 2008) . However, in spite of an inverse correlation in the levels of MTA1 and E-cadherin in tumor cells, it remains unknown whether TGF-b1-signaling, a known modifier of E-cadherin expression and EMT, require MTA1. Here, we examined the role of MTA1 in TGF-b1-signaling and discovered that MTA1 is a target and an essential modifier of TGF-b1-signaling in epithelial cells.
Results

MTA1 is required for TGF-b1-signaling in epithelial cells
In spite of a widespread upregulation of MTA1 in breast cancer and metastasis, it remains unknown whether MTA1 has any role in EMT, a prerequisite for tumor metastasis. Hence, we wished to investigate whether MTA1 has a role in TGF-b1-induced EMT using HC11 cells as a model system. HC11 cells are mammary epithelial cells with polygonal morphology while TGFb1 stimulates its trans-differentiation into mesenchymal phenotype with an elongated morphology ( Figure 1a ) (Radisky, 2005) . We found that MTA1-depletion by selective small interfering RNA (siRNA) compromises the ability of TGF-b1 to induce elongated morphology in HC11 cells (Figure 1b) . In parallel, MTA1-knockdown also suppressed the effect of TGF-b1 to upregulate a-SMA (Figure 1c ) and to downregulate epithelial marker E-cadherin (Figure 1c) . Furthermore, HC11 cells stably overexpressing MTA1 exhibited a distinct mesenchymal morphology (Figure 1d ) as well as downregulation of E-cadherin (Figure 1e ). MTA1 overexpression or knockdown in the NMuMG primary mammary cells also modulated the levels of E-cadherin and a-SMA (Figures 1f and g ). These findings suggested that MTA1 is a modifier of TGF-b1-signaling and its net levels affect EMT.
TGF-b1-signaling induces MTA1 expression through CDP During the course of preceding studies, we consistently noticed that TGF-b1-stimulation of cells accompanies with an increased expression of MTA1 protein (Figures 1c  and f) , raising the hypothesis that MTA1 might be regulated by TGF-b1-signaling. To test this notion, we next treated HC11 cells with TGF-b1 and showed that indeed, TGF-b1 stimulates the level of MTA1 protein and mRNA (Figures 2a and b ) and represses the expression of E-cadherin protein ( Figure 2a ) and that transcriptional inhibitor actinomycin D substantially reduces the levels of TGF-b1-inducible MTA1 mRNA and protein (Figures 2b and c) . These findings suggested that MTA1 may be a target of TGF-b1.
MTA1 gene resides on chromosome 14q32.3 locus in human and chromosome 12f1 locus in mouse. To study the TGF-b1 regulation of MTA1 transcription, we cloned the 5 kb promoter region of mouse MTA1 and generated a series of promoter-luc reporter systems (Supplementary Figure S1a) . The MTA1 region of À5200 to À2872-bp upstream to the first codon ATG showed the maximum potential for promoter-like sequence. Both the minimal and full-length MTA1 promoter was equally responded to TGF-b1 stimulation ( Figure 2d and Supplementary Figure S1a) .
As MTA1 is involved in promoting tumor invasiveness and motility (Mahoney et al., 2002; Hofer et al., 2004) and is now induced by TGF-b1 (this study), we next performed Transfac analysis of the MTA1 promoter to identify the bindings sites for transcription factors that might be responsive to TGF-b1 signaling and thus, involved in the noted TGF-b1 stimulation of MTA1 transcription. We found that MTA1 promoter harbors binding sites for TGF-b1-related factors CDP, CEBPa and YY1 (Supplementary Figure S1b and Supplementary Table S1 ). CDP is a direct target of TGF-b1 signaling and in turn, regulates other TGF-b1-responsive genes and promotes tumor cell invasiveness (Michl et al., 2005; Michl and Downward, 2006) , while YY1
and CEBPa (CAAT enhancer-binding protein) inhibits TGFb1 signaling MacLellan et al., 1994; Kurisaki et al., 2003; Gery et al., 2005) . As TGFb1 signaling stimulates (and not inhibits) MTA1 transcription, we choose to concentrate on CDP in the subsequent studies.
The presence of seven consensus motifs for CDP on the MTA1 promoter provided clues that MTA1 might be regulated by TGF-b1-responsive transcription factors. We found that transient expression of CDP alone is sufficient to induce MTA1 promoter activity (Figure 2e ), suggesting that TGF-b1 may indeed, utilize CDP to stimulate MTA1 transcription (Supplementary Figure  S2a) . To validate this finding, we next examined the impact of CDP-knockdown on the ability of TGF-b1 to stimulate MTA1 transcription. We found that CDPdepletion prevents TGF-b1 stimulation of MTA1 promoter activity ( Figure 2f ). As expected, TGF-b1 stimulates the expression of CDP and a-SMA. Interestingly, CDP-knockdown also abolished the stimulation of the endogenous MTA1 and a-SMA by TGF-b1 ( Figure 2g ). As Smad4-dependent signaling is involved in the transcriptional regulation of CDP (Michl et al., 2005) , we next examined the effect of Smad4-knockdown on MTA1 transcription. We found that Smad4-depletion prevents the ability of TGF-b1 stimulation of MTA1 transcription (Figure 2h ). These results suggest a mechanistic role of CDP in TGF-b1 stimulation of MTA1 transcription.
To gain a deeper insight into the molecular mechanism involved in CDP regulation of MTA1 stimulation, we next mapped the recruitment of CDP to MTA1 promoter by chromatin immunoprecipitation (ChIP). CDP was recruited to regions II, IV, V and VI of the MTA1 promoter (Figure 3a) . Interestingly, CDP interaction at these regions was further increased on TGF-b1 treatment. To further characterize the responsive active sites on MTA1 promoter, we determined the status of acetylated histone H4 at all these regions. We found that TGF-b1 stimulation leads to recruitment of acetylated histone H4 at region IV and VI, suggesting that these could be the functional regions in vivo (Figure 3b ). On the other hand, there was no recruitment of acetylated histone H3 onto MTA1 promoter in TGF-b1-stimulated cells (Supplementary Figure S2b) . Sequential doubleChIP analysis involving CDP followed by acetylated H4 antibodies indicated that CDP and acetyl histone H4 are co-recruited only to region VI of MTA1 promoter ( Figure 3c ).
Next, we examined whether CDP directly binds to the region VI of MTA1 promoter, which harbors two putative sites for CDP. Probes for both sites, designated BS1 and BS2, were used to examine binding to glutathione S-transferase-CDP by electrophoretic mobility shift assay (EMSA). Results indicated that CDP does not bind to region BS1 but effectively binds to region BS2, indicating that BS2 may represent the actual CDP-binding site in the region VI of MTA1 promoter (Figure 3d and Supplementary Figure S2c) . Accordingly, results from the nuclear extracts from control and TGF-b1-stimulated HC11 cells revealed the formation of CDP-DNA complex(s) at the BS2 region and the observed complex could be supershifted by an anti-CDP-Ab but not control immunoglobulin G (IgG) (Figure 3e ). To further confirm the binding of CDP to the BS2 motif in the region VI in vivo, we performed ChIP for CDP recruitment to these regions using specific primers and found that, indeed, CDP-binding sites are limited to the BS2 motif in region VI of MTA1 promoter in TGF-b1-stimulated cells (Figure 3f ). These findings suggest that TGF-b1 utilizes CDP to stimulate MTA1 transcription (Figure 3g ).
TGF-b1-mediated FosB expression requires MTA1
To understand the physiologic significance of TGF-b1 regulation of MTA1 expression, we next investigated the possibility of a role of MTA1 in TGF-b1 signaling. Although these studies were in-progress, results from ongoing, in-house, genome-wide analyses of MTA1 targets in MCF-7 cells using NimbleGen promoter platform revealed that MTA1 might be recruited to genes involved in the TGF-b1 pathway (Supplementary Table S2 ). Since previous study has implicated Fos family genes in TGF-b1-induced EMT (Eferl and Wagner, 2003) and because FosB is now being identified as a MTA1 target in our ChIP-on-ChIP analysis (this study), we decided to focus on FosB as a potential MTA1 target and asked whether MTA1 is required for TGF-b1 induction of FosB. We found that both TGF-b1 stimulation as well as MTA1 overexpression alone induces FosB mRNA or protein in HC11 cells (Figures 4a and b) . Further selective siRNA-mediated knockdown of MTA1 in HC11 cells reduced FosB mRNA and protein (Figures 4c and d) . Since the outcome of siRNA-mediated knockdown studies is dependent on the extent of target knockdown, we next examined the effect of MTA1-depletion in mouse embryonic fibroblasts (MEFs) from wild-type and MTA1 À/À mice treated with TGF-b1. We found that MTA1-deficiency substantially compromised the ability of TGF-b1 to induce FosB protein expression and promoter activity in MEFs ( Figure 4g ). This may be due to the fact that actinomycin D is a broad range transcriptional inhibitor and as expected, it also blocked TGF-b1 stimulation of MTA1, a new FosB co-activator (this study). Consistent with these results, we found that MTA1 overexpression induces FosB-promoter activity in HC11 cells (Figure 4h ).
To determine the underlying mechanism of MTA1 regulation of FosB expression, we next carried out a ChIP-based promoter walk in HC11 cells treated with or without TGF-b1. We found the recruitment of MTA1 to only region III (À644 to À794) of the FosB-promoter and TGF-b1 stimulation further enhances such recruitment ( Figure 5a ). We also found that RNA Pol II and MTA1/Pol II co-activator complex is also recruited onto region III of FosB-promoter (Figure 5a ). Interestingly, complexes containing MTA1/acetyl hitsone H4 but not MTA1/HDAC2 is recruited to the same region, supporting the functional active nature of the region ( Figure 5a ). A schematic representation of recruitment of MTA1, RNA Pol II and acetyl histone H4 onto FosBpromoter is presented in Supplementary Figure S3a .
Transfac analysis of the region III of FosB-promoter revealed the presence of one potential AP-1 site (5 0 -CGAGTCACAC-3 0 , À708 to À717). Members of the Jun/Fos family form hetero-or homo-dimers and constitute AP-1 transcription factors. Hence, we next carried out single or sequential c-Jun-Ab-based ChIP analysis onto FosB-promoter. To our surprise, c-Jun and MTA1/c-Jun complexes are also recruited to the region III of FosB-promoter ( Figure 5a ). To determine whether c-Jun has a mechanistic role along with MTA1 in TGF-b1-mediated stimulation of FosB expression, we examined the effects of c-Jun alone or in combination of MTA1 on FosB-promoter (À1000 to þ 307) and a truncated FosB-promoter lacking AP-1 site (À603 to þ 307) in TGF-b1-stimulated cells. We found that MTA1 and c-Jun stimulates FosB-promoter activity in a cooperative manner and that AP-1 site on FosBpromoter is indispensable for stimulation of Fos-B activity by MTA1 and/or TGF-b1 (Figure 5b ). Collectively, these results suggest that MTA1/Pol II/c-Jun may exist in the same complex under physiologic condition. To support this notion, we showed that indeed, RNA Pol II and c-Jun could be co-immunoprecipitated along with MTA1 in both basal and TGF-b1-stimulated HC11 (g) Western blot analysis for E-cadherin and a-SMA expression from the cell lysates of NMuMG cells treated with specific MTA1-siRNA in presence and absence of TGF-b1. NMuMG cells were transfected with control siRNA and MTA1-siRNA. After 48 h of transfection, cells were serum starved and treated with TGF-b1 for 12 h. Cells were harvested and western blot analysis was carried out with specified antibodies. (a-g) cells were treated with 2 ng/ml of TGF-b1 for 12 h. cells but the amount of co-IP proteins were significantly increased in stimulated cells, presumably because of increased levels of MTA1 protein (Figure 5c ). To demonstrate a potential direct binding of c-Jun to FosB-promoter, we next performed EMSA using the PCR product encompassing region III of the murine FosB-promoter, and nuclear extracts from TGF-b1-stimulated HC11 cells. We found that TGF-b1 stimulation of cells promotes the formation of distinct protein/ DNA complexes. To gain insights into the components of complexes, we attempted to supershift the protein/ DNA band by inclusion of anti-MTA1-Ab, anti-cJun-Ab or both (Figure 5d ). Interestingly, anti-MTA1 or anti-c-Jun-antibodies had similar effects on the mobility of the protein/DNA complex. However, the complex could be further super shifted by co-treatment Results were presented in terms of fold change and the values represent the mean of ± s.e. from three independent transfection experiments. (e) MTA1 promoter activity after co-transfecting with CDP-pMX in presence of TGF-b1 (2 ng/ml for 12 h) in HC11 cells. CDP-pMX plasmid with different concentration (0.25 and 1 mg) was transfected along with MTA1-pGL3 luciferase reporter plasmid and promoter luciferase assay was carried out as described in figure legend 2d. (f) MTA1 promoter activity in TGF-b1 (2 ng/ml for 12 h) activated HC11 cells with and without CDP knockdown. HC11 cells were transfected with CDP-siRNA and after 36 h of transfection MTA1-pGL3 luciferase reporter plasmid and pCMVb vector carrying b-galactosidase gene were transfected and luciferase assay was carried out as described in figure legend 2d. (g) Western blot analysis of MTA1, CDP and a-SMA protein expression from the cell lysates of HC11 treated with TGF-b1 (2 ng/ml for 12 h) after selective knock down of CDP. (h) MTA1 promoter activity in TGF-b1 (2 ng/ml for 12 h) activated HC11 cells with and without Smad4 knockdown. After Smad4 knockdown using Smad4-siRNA, HC11 cells were transfected with MTA1-pGL3 luciferase reporter plasmid following the method described earlier.
MTA1, a new effector of TGF-b1 signaling SB Pakala et al with both antibodies, suggesting the existence of MTA1-cJun complex and its ability to interact FosB-DNA. In brief, these findings reveal that MTA1 behaves as a coactivator in stimulating the expression of Fos-B in TGFb1-stimulated epithelial cells.
MTA1/HDAC2/FosB corepressor complex downregulates E-cadherin
On the basis of the complementary DNA microarray analysis, an earlier study has suggested but not established that FosB may negatively regulate Ecadherin (Ohnishi et al., 2008) . Having shown that MTA1 is a target of TGF-b1 signaling and has an important role in TGF-b1-mediated stimulation of FosB expression, we next investigated the role of this newly identified MTA1-FosB pathway in the regulation of E-cadherin. We next examined the effects of MTA1 or FosB on the regulation of E-cadherin transcription. Co-expression of either MTA1 or FosB substantially downregulates E-cadherin promoter activity in HC11 cells and there is no addition effect of TGF-b1 stimulation (Figure 6a ). To demonstrate a role of MTA1 in the regulation of E-cadherin transcription, (a-f) Cells were treated with 2 ng/ml of TGF-b1 for 12 h.
MTA1, a new effector of TGF-b1 signaling SB Pakala et al
we showed a significant reduction in the ability of TGFb1 to inhibit E-cadherin promoter activity in MTA1
À/À MEFs ( Figure 6b ). However, overexpression of FosB, a target of MTA1, could inhibit E-cadherin promoter activity in MTA1 À/À MEFs. To independently validate these results, we next showed that FosB knockdown in HC11 cells (Figure 6c ) antagonizes the ability of TGF-b1 stimulation or MTA1 overexpression to inhibit E-cadherin transcription (Figure 6c ). These findings suggest that FosB may constitute a downstream effect of MTA1 in repressing E-cadherin transcription, at-least in-part.
To delineate the molecular mechanism involved in the observed repression of E-cadherin transcription by MTA1-FosB pathway, we next performed a ChIPbased promoter walk onto E-cadherin promoter. We found the recruitment of MTA1, FosB and MTA1/FosB complex to the regions II and III of E-cadherin promoter (Figure 7a ) but not to region I, IV, V and VI (Supplementary Figure S3b) in HC11 cells. Interestingly, TGF-b1 stimulation of HC11 cells results in an enhanced recruitment of these proteins onto E-cadherin promoter ( Figure 7a ). As MTA1 is known to interact with HDACs (Molli et al., 2008) and the fact that both MTA1 and HDAC2 are components of the nucleosome remodeling and histone deacetylation corepressor (Manavathi and Kumar, 2007) we next showed that HDAC2 as well as FosB/HDAC2 complex are also recruited to þ / þ and MTA1 À/À MEFs after co-transfecting with MTA1 in presence and absence of TGF-b1. FosB-pGL3 luciferase reporter plasmid and pCMVb vector carrying b-galactosidase gene were transfected and after 36 h of transfection cells were serum starved and treated with TGF-b1. Luciferase assay was carried out as mentioned in figure legend 2d. (g) qPCR analysis for FosB mRNA expression in HC11 cells treated with TGF-b1 in presence and absence of actinomycin D (250 ng/ml). Actinomycin D was added 1 h before the TGF-b1 treatment. The results were represented in terms of fold change after normalizing the FosB mRNA levels with b-actin mRNA. Each value represents the mean of ± s.e. of three independent experiments. (h) FosB-promoter activity in HC11 cells after co-transfecting with MTA1 in presence and absence of TGF-b1. Luciferase assay was carried out in triplicates and results were presented in-terms of fold change and the values represent the mean of ± s.e. from the three independent transfection experiments. (a, c-f, h) Cells were treated with 2 ng/ml of TGF-b1 for 12 h. the regions II and III of E-cadherin promoter in TGF-bresponsive manner (Figure 7a ). We also showed that knockdown of FosB in HC11 cells inhibits MTA1 recruitment onto E-cadherin DNA, while there was no effect of MTA1-siRNA on the recruitment of FosB to E-cadherin DNA (Figure 7b ). In addition to this, no effect was observed on the recruitment of FosB to E-cadherin promoter even in MTA1 þ / þ and MTA1 Figure S3c) . This is presumably, due to downstream nature of FosB in relation to MTA1. These findings suggested the possibility of an enhanced interaction among MTA1, HDAC2 and FosB in TGFb1-stimulated cells. Indeed, we found that both MTA1 and HDAC2 could be efficiently co-immunoprecipated along with FosB in TGF-b1-stimulated HC11 cells (Figure 7c ). To demonstrate a potential direct binding of FosB to the mouse E-cadherin-DNA, we next performed EMSA using the PCR product encompassing region II or III (Figure 7d ) and nuclear extracts from TGF-b1-stimulated HC11 cells. We found the formation of distinct protein/DNA complexes. Interestingly, the binding of these complexes to the test DNA could be super shifted by the inclusion of anti-FosB or anti-MTA1 but not control IgG; while co-incubation of anti-MTA1 and FosB antibodies resulted in an additional retardation of mobility of the complex (Figure 7d ). These findings suggest a potential role of MTA1/FosB/ HDAC2 corepressor complex in TGF-b1-mediated suppression of E-cadherin transcription. Consistent with these results, we showed that FosB downregulation in HC11 leads to an enhanced E-cadherin expression (Figure 7e ). In summary, findings presented here suggest that TGF-b1 signaling targets MTA1 and that MTA1 has an important role in the action of TGF-b1and in supporting the expression of FosB, which in turn, facilitates the repression of E-cadherin-a target of both TGF-b1 and MTA1 in epithelial cells (Figure 8 ).
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Discussion
Our core findings that MTA1 downregulates the expression of E-cadherin has introduced a new regulatory player in the event of EMT. E-cadherin downregulation is one of the principal events during EMT in embryonic development and cancer progression. EMT represents a key event in the progression of tumor cells to dedifferentiated and invasive phenotypes (Thiery, (Radisky, 2005; Hugo et al., 2007) . It is evident that many transcriptional factors, such as Snail, Slug, SIP1, Twist, LIV1 and dEF were involved in the repression of E-cadherin (Thiery, 2002; Zavadil and Bottinger, 2005) and there-by stimulates the process of epithelial plasticity in breast cancer cells. Although many signaling pathways converge with the function and expression of E-cadherin, the transcriptional regulation of E-cadherin expression continue to be poorly understood. In this context, this study establishes a definitive contribution of MTA1 in downregulation of E-cadherin expression, leading to EMT. As MTA1 regulates its target genes by acting either as a transcriptional corepressor or co-activator (Mazumdar et al., 2001; Gururaj et al., 2006; Balasenthil et al., 2007; Molli et al., 2008) , our results show that E-cadherin is target of MTA1 and it downregulates E-cadherin expression at the level of transcription by directly interacting with its promoter as a part of FosB/HDAC2 complex.
2002) and in cancer metastasis
MTA1 overexpression is associated with metastatic growth of cell lines and with invasive growth of tumors (Manavathi and Kumar, 2007) . Studies presented here provide a mechanistic basis of earlier correlative studies between MTA1 and E-cadherin Tong et al., 2007; Dannenmann et al., 2008) . Recently, von Burstin et al. (2009) reported the role of HDACs in silencing of E-cadherin during the metastatic process of pancreatic cancer cells. Although there is existence of a strong relationship between the MTA family, HDACs and E-cadherin, the study explains the mechanistic basis of the regulation of E-cadherin by these molecules during breast cancer progression. In this context, our study demonstrates the contribution of MTA1 in the regulation of TGF-b1-mediated E-cadherin repression, which may be one of the mechanisms that attributes to the metastatic function of MTA1. Overall, our results strongly suggest that MTA1 induces EMT by regulating the expression of E-cadherin, which has a key role in regulating the motility, invasion and metastatic potential of cancer cell.
Materials and methods
Antibodies and cell culture Antibodies against MTA1 (A300-280A), and RNA Pol II (A300-653A) were purchased from Bethyl labs, Montgomery, TX, USA. HDAC2 (sc-9959), FosB (sc-48), E-cadherin (sc-1500), c-Jun (sc-1694) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). a-SMA (A2547), normal mouse IgG, rabbit IgG and antibodies against vinculin were purchased from Sigma Chemical Co (St Louis, MO, USA). Acetyl histone H3 (06-599) and H4 (06-598) antibodies were purchased from United Biotech Inc. (Mountain View, CA, USA). All cells were cultured in Dulbecco's modified Eagle's medium/F12 medium supplemented with 10% fetal bovine serum. HC11 cells were maintained in RPMI-1640 medium supplemented with 10% fetal calf serum, 10 ng/ml epidermal growth factor and 5 mg/ml insulin. TGF-b1 was obtained from PeproTech Inc., Rocky Hill, NJ, USA. Cells were treated with TGF-b1 (2 ng/ml of the medium for 12 h) after 12-14 h of serum starvation in serum-free medium. Quantitative PCR For quantitative PCR total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and first-strand complementary DNA synthesis was carried out with SuperScript II reverse transcriptase (Invitrogen) using 2 mg of total RNA and poly (dT) primer. Quantitative reverse transcriptase-PCR was performed with the gene-specific primers listed in Supplementary Table 3 using a 7900HT sequence detection system (Applied Biosystems, Foster City, CA, USA). The levels of mRNA of all the genes were normalized to that of b-actin mRNA.
Reporter and immunoprecipitation assays MTA1-luc, FosB-luc and E-cadherin-luc assays were performed according to the manufacturer's instructions (Promega, Madison, WI, USA), and the results were standardized against the b-galactosidase activity, an internal control. Some assays were performed in the presence of control siRNA or MTA1 siRNA and FosB-siRNA. Cell lysates were prepared in RIPA lysis buffer, and western blot analysis was performed as previously described (Kumar et al., 2002) . For immunoprecipitation assays, 1 mg of cell lysate was incubated with MTA1 or FosB antibody and agarose beads with constant rotation followed by extensive washing with NP-40 buffer (20 mM HEPES [pH 7.6], 150 mM KCl, 1 mM DTT, 0.1% NP-40 and 8% glycerol). The immunoprecipitated proteins were resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to nitrocellulose membrane and analyzed by western blotting using antibodies for TGF-b1 signaling components.
Cloning of murine MTA1 promoter Full-length murine MTA1 promoter and its deletion constructs were generated by following the procedures described elsewhere .
siRNA transfection siRNA against MTA1 and negative control siRNA were purchased from Dharmacon (Lafayette, CO, USA). HC11 cells were seeded at 40% density the day before transfection in six-well plates, and siRNA transfections were performed with oligofectamine reagent (Invitrogen) according to the manufacturer 0 s instructions. Cells were harvested 48 h after transfection and cell lysates were prepared.
ChIP assay
ChIP assays were performed as described previously (Mazumdar et al., 2001) . Briefly, cells were crosslinked with formaldehyde (1% final concentration) and sonicated on ice to fragment the chromatin into an average length of 500 bp-1 kb. The lysates were diluted using chromatin-dilution buffer. MTA1 or CDP or acetyl histone H4 or acetyl Histone H3 or Pol II or HDAC2 or FosB or c-Jun or mouse IgG were used to immunoprecipitate the respective antigens at 4 1C overnight. Protein A sepharose beads saturated with bovine serum albumin and single-strand DNA were added to the lysate to isolate the antibody-bound complexes. The beads were washed to remove nonspecific binding, and the antibody-bound chromatin was eluted. The eluate was 'de-crosslinked' by heating at 65 1C for 6 h. RNase was added during this step to digest the RNA contaminants. Samples were treated with proteinase K for 1 h at 45 1C to digest the immunoprecipitated proteins, and finally, the DNA was extracted using the phenol chloroform method. For the double ChIP experiment, an initial ChIP assay was done with either MTA1 or FosB antibody to immunoprecipitate MTA1-bound chromatin, which was eluted from the protein A sepharose beads and subjected to a second ChIP assay with either Pol II or anti-HDAC2 antibody. With the DNA isolated at the end of the ChIP analysis, PCR was performed using the primers mentioned in Supplementary Table 4 .
Electrophoretic mobility shift assay Nuclear extracts were prepared using a Nonidet P-40 lysis method (Bui-Nguyen et al., 2010) EMSA for CDP or FosB or E-cadherin DNA binding was performed using the annealed and [g 32 P] ATP end-labeled oligonuclotides (Supplementary Table 5) or PCR products in a 20-ml reaction mixture for 15 min at 20 1C. Samples were run on a nondenaturing 5% polyacrylamide gel and imaged by autoradiography. Specific competitions were performed by adding a 10 folds excess of competitor to the incubation mixture, and supershift EMSAs were performed by adding 1.5 ml of the either MTA1 or CDP or FosB or c-Jun antibodies.
Confocal analysis
After transfecting HC11 cells with MTA1-siRNA or FosB-siRNA, E-cadherin and a-SMA expression was determined by indirect immunofluorescence. The cells were grown on sterile glass cover slips, fixed in 4% paraformaldehyde, permeabilized in 0.1% Triton X-100 and blocked in 10% normal goat serum in phosphatebuffered saline. Cells were incubated with FosB or E-cadherin Figure 8 Schematic representation of MTA1 regulation of FosB and E-cadherin expression: TGF-b1 stimulation of mammary epithelial cells results in the induction of MTA1. Once MTA1 is induced, it forms a co-activator complex along with c-Jun and Pol II and gets recruited to FosB-promoter leading to induced FosB expression, which in turn, represses the transcription of E-cadherin by recruiting on to its chromatin along with MTA1 and HDAC2. Dotted line shows MTA1-independent regulation of E-cadherin by other mechanisms not investigated here.
antibody, washed three times in phosphate-buffered saline, and then incubated with goat anti-rabbit secondary antibodies conjugated with 488-Alexa from Molecular Probes (Eugene, OR, USA). The 4,6-diamidino-2-phenylindole (Molecular Probes) was used as a nuclear stain. Microscopic analysis was performed using an Olympus FV300 laser-scanning confocal microscope (Olympus America Inc., Melville, NY, USA) using sequential laser excitation to minimize fluorescence emission bleed-through.
Statistical analysis
The results are given as the mean±s.e. Statistical analysis of the data was performed by using Student's t-test.
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